Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin - 1 in cervical cancer cells. (ptglab.com)
The chemotherapy drug bortezomib (marketed by Millennium Pharmaceuticals under the brand name Velcade) takes advantage of this reliance and targets the proteasome's function. (sciencedaily.com)
A phase I trial with 25 patients combining bortezomib and HCQ for relapsed or refractory myeloma achieved autophagy inhibition and was tolerated. (sciencedaily.com)